Abstracts tagged "interstitial lung disease"

Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…
Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Masataka Kuwana², Ning Li³, Julio Charles⁴, Faye N. Hant⁵, Galina S. Bogatkevich⁶, Tanjina Akter⁶, Michael Roth⁷, Hyun J. Grace Kim⁸, Jonathan Goldin⁹, Dinesh Khanna¹⁰, Philip J. Clements¹¹, Daniel E. Furst⁷, Robert Elashoff¹², Rick Silver¹³ and Shervin Assassi¹⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of California, Los Angeles, Los Angeles, CA, ¹²University of California, Los Angeles, Los Angeles, CA, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
Abstract Number: 2015 • 2018 ACR/ARHP Annual Meeting
Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies
Sara Sabbagh¹, Iago Pinal-Fernandez¹, Takayuki Kishi², Ira N. Targoff³, Frederick W. Miller², Lisa G. Rider² and Andrew Mammen^1,4, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Environmental Health Sciences, National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA) found in adult and juvenile idiopathic inflammatory myopathies (JIIM) often confer a specific disease phenotype.…
Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting
Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Osman Bhatty¹, Rouhin Sen¹, Douglas Moore² and Joseph Nahas³, ¹Department of Medicine, CHI Creighton University Medical Center, Omaha, NE, ²Department of Pulmonary/Critical Care, CHI Creighton University Medical Center, Omaha, NE, ³Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…
Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Dinesh Khanna², Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Lynette Keyes-Elstein⁴, Ashley Pinckney⁴, Ellen Goldmuntz⁵, Robert Elashoff⁶ and Keith Sullivan⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵NIAID, NIH, Bethesda, MD, ⁶University of California, Los Angeles, Los Angeles, CA, ⁷Duke University, Durham, NC
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…
Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting
Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration
Richard Bell¹, Emily Wu^1,2, Homaira Rahimi³ and Edward Schwarz^1,4,5, ¹Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ²Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ³Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, ⁴University of Rochester, Rochester, NY, ⁵Univ of Rochester Med Ctr, University of Rochester School of Medicine and Dentistry, Rochester, NY
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…
Abstract Number: 1684 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Yuki Ichimura, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Tomoaki Higuchi, Yasuhiro Katsumata and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is the disease characterized by organ fibrosis with unknown etiology, and pulmonary involvement is one of major cause of death. However,…
Abstract Number: 1695 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease
Robert L. Mango¹, Eric L. Matteson², Cynthia S. Crowson³, Jay H. Ryu⁴ and Ashima Makol², ¹Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Interstitial lung disease (ILD) is a major contributor to morbidity and mortality in systemic sclerosis (SSc). We sought to identify the distribution of clinical…
Abstract Number: 1702 • 2017 ACR/ARHP Annual Meeting
Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore
Maria Noviani¹, Seyed Ehsan Saffari², Sandra Mei Yu Kua¹, Grace Yin Lai Chan³, Gim Gee Teng⁴, Weng Giap Law⁵, Amelia Santosa⁴, Anita Yee Nah Lim⁴, Swee Cheng Ng¹ and Andrea Hsiu Ling Low¹, ¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, ²Center for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore, Singapore, ³Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, SIngapore, Singapore, ⁴Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, Singapore, ⁵Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, Singapore
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of mortality in patients with systemic sclerosis (SSc). We aimed to determine…
Abstract Number: 2008 • 2017 ACR/ARHP Annual Meeting
“Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”
Diego Baenas¹, Maira Orozco², María Eugenia Olmos³, Luis Lasca⁴, Paula Riba⁵, Patricio Muszinsky⁵, Juan Pablo Pirola⁶, Verónica Saurit⁷, Alejandro Alvarellos⁷, Ana C. Alvarez⁸, Soledad Retamozo^9,10, Nadia Riscanevo^7,11, Janet Flores¹², Ariel Blua³, Ana María López¹³, Gustavo Muiño¹⁴, Santiago Orozco¹⁵ and Francisco Caeiro¹⁶, ¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Postgraduate Career of Rheumatology Catholic University of Córdoba., Cordoba, Argentina, ²Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³Pulmonary, Pulmonary Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁴Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁵Radiology, Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁶Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ⁷Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ¹⁰Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Pulmonary Unit, Pulmonary Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁴Radiology, Radiology Unit,Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁵Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁶Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina
Background/Purpose: Connective tissue diseases (CTD) can cause intrathoracic involvement, increasing patients morbidity and mortality. High-resolution computed tomography (HRCT) is a key method for evaluation of…
Abstract Number: 2114 • 2017 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?
Sepehr Mesdaghinia¹, Julio Arturo Huapaya², Brainerd Ewarien² and Virginia D. Steen¹, ¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²Medicine, MedStar Georgetown University Hospital, Washington, DC
- Background/Purpose: Interstitial lung disease (ILD) can be an early manifestation of an occult connective tissue disease (CTD). It is important to separate these patients…
Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama^1,2, Ryusuke Yoshimi^1,2, Maasa Tamura^2,3, Naoki Hamada^1,2, Hideto Nagai^1,2, Naomi Tsuchida^1,4, Yosuke Kunishita^1,2, Yutaro Soejima^1,2, Daiga Kishimoto^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^1,5, Yohei Kirino^1,2, Shigeru Ohno^1,6 and Hideaki Nakajima², ¹Y-CURD Study Group, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Y-CURD Study Group, Yokohma, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, ⁶Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…